MedTrace Logo

Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants

NCT02692599 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1150

Last updated 2017-10-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate the immunogenicity and safety of a live attenuated mumps vaccine in healthy infants between 8 - 18 months old with a commercialized live attenuated mumps vaccine as the control vaccine.

Conditions

Interventions

BIOLOGICAL

investigational live attenuated mumps vaccine

The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.

BIOLOGICAL

control live attenuated mumps vaccine

The control vaccine was manufactured by Zhejiang VACN bio-pharmaceutical Co. Ltd.

Sponsors & Collaborators

  • Sinovac (Dalian) Vaccine Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jingchen Ma · Hubei Provincial Center for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
8 Months
Max Age
18 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2016-03-31
Completion
2016-07-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02692599 on ClinicalTrials.gov